Understanding how protein pathways affect age-related brain diseases
Official title: Mechanisms of neurodegenerative diseases: intersections with ubiquitin pathways
Funded at University of Michigan at Ann Arbor · NIH-11083079 · Data updated 2026-11-12
This study is looking at how certain proteins that help keep our cells healthy can go wrong in diseases like Alzheimer's and Parkinson's, with the hope of finding new ways to treat these conditions and improve patients' lives.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | May 1, 2021 |
| Project end | April 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $1,087,708 |
| NIH project number | 5R35NS122302-05 |
| Project ID | NIH-11083079 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include older adults experiencing symptoms of neurodegenerative diseases or those at risk due to genetic factors.
✕Less likely to help
Patients with neurodegenerative diseases unrelated to age or those in very early stages of disease may not receive direct benefits from this research.
What this research studies
This research investigates the role of proteins involved in the ubiquitin pathways, which are crucial for maintaining cellular health, particularly in the context of age-related neurodegenerative diseases. By examining how these proteins aggregate and malfunction in diseases like Alzheimer's and Parkinson's, the research aims to uncover new therapeutic targets. The study employs a variety of innovative tools and models to explore the mechanisms behind these diseases, focusing on how disruptions in ubiquitin signaling contribute to neurodegeneration. Patients may benefit from insights that could lead to novel treatments for these debilitating conditions.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that slow down or prevent the progression of age-related neurodegenerative diseases.
How similar studies have gone: Previous research has shown promising results in targeting ubiquitin pathways for neurodegenerative diseases, indicating a potential for success in this approach.
Where this research is happening
-
University of Michigan at Ann Arbor
Ann Arbor, United States Active
Researchers
- Principal investigator: Paulson, Henry L — University of Michigan at Ann Arbor
- Study coordinator: Paulson, Henry L
Related research
Other NIH-funded projects on the same topics.
-
Developing small molecules to treat TDP-43 related brain diseases
A potential new drug candidate (XL20) for diseases like Alzheimer’s and other dementias linked to TDP-43 protein problems is being developed and refined for people who live with these conditions.
-
Tau filament structure in Alzheimer’s and related dementias
Aims to map the detailed 3D shapes of tau protein filaments found in human brain diseases to help develop better diagnostics and treatments for Alzheimer’s-related dementias.
-
Targeting RNA Splicing Abnormalities in ALS/FTD
A research team aims to understand and correct abnormal RNA splicing in ALS and related brain diseases to help patients in the future.
-
Blood-brain barrier–friendly imaging agents for neurodegenerative diseases
A researcher team will test new imaging agents that can cross the brain barrier to help detect Alzheimer’s and related diseases earlier and more accurately.
-
Brain cell–derived EV markers to differentiate Alzheimer’s and related dementias
A Mayo Clinic team is testing brain-cell–specific tiny particles in blood to tell apart Alzheimer’s disease and similar dementias using advanced machine-learning analysis.
-
Fisetin approach to reduce vulnerability to community infections in aging veterans
A patient-friendly look at a study testing whether the natural compound fisetin can help aging Veterans stay healthier when they face common infections.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.